NCT01716156View on ClinicalTrials.gov

A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 18, 2013

Primary Completion Date

December 9, 2013

Study Completion Date

March 12, 2014

Conditions
Hepatitis C
Interventions
DRUG

Grazoprevir

Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment

DRUG

Ribavirin

Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01716156 - A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039) | Biotech Hunter | Biotech Hunter